• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 9, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

MU researchers describe catatonia in Down syndrome

Bioengineer by Bioengineer
November 19, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

First longitudinal study highlights positive responses to established catatonia therapies

IMAGE

Credit: MU News Bureau


COLUMBIA, Mo. – Down syndrome, due to an extra chromosome 21, occurs in 250,000 children and adults in the United States, making it the country’s most common chromosomal disorder. Inherited heart defects, thyroid cancer, celiac disease and developmental disabilities are common Down syndrome complications. Only recently has catatonia, a behavioral condition marked by new onset immobility, mutism, withdrawal and other behavioral abnormalities, been recognized in Down syndrome.

While considerable research has been done on Down syndrome, little is known about associated catatonia. Now, researchers at the University of Missouri have conducted the first longitudinal study of consecutively diagnosed individuals with catatonia in order to identify the most effective treatments and outcomes.

Judith Miles, professor emerita of child health-genetics in the MU Thompson Center for Autism and Neurodevelopmental Disorders, thoroughly assessed seven adolescents with Down syndrome and diagnosed with catatonia between 2013 and 2018.

“As this was the first well-studied group of patients with Down syndrome who developed catatonia, we collected a comprehensive data set of medical, developmental, demographic, family, social and genetic information,” Miles said. “By involving the patients’ families throughout the process, we were able to monitor progress over time in a patient-centered way.”

Miles found catatonia in young people with Down syndrome, for the most part, resembles catatonia complicating other psychiatric and medical disorders. Lorazepam, a sedative drug that helps restore the balance of neurotransmitters in the brain, and electroconvulsive therapy, which involves a brief electrical stimulation of the brain while the patient is under anesthesia, both resulted in reduced behavioral symptoms over time. The research highlights the importance of sustained treatment to help patients with Down syndrome and catatonia maintain recovery long-term.

“This research can help families, physicians and psychiatrists who take care of kids with catatonia,” Miles said. “Our main goal is to enhance medical services and treatment options in order to ultimately improve health outcomes.”

###

The study “Catatonia in Down syndrome: systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients” was recently published in Neuropsychiatric Disease and Treatment.

Media Contact
Brian Consiglio
[email protected]
573-882-9144

Original Source

https://news.missouri.edu/2019/mu-researchers-describe-catatonia-in-down-syndrome-and-highlight-positive-responses-to-established-catatonia-therapies/

Related Journal Article

http://dx.doi.org/10.2147/NDT.S210613

Tags: AlzheimerGeneticsHealth CareMedicine/Healthneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Glaucoma Treatment Insights from French Nationwide Survey

September 9, 2025

Preduodenal Portal Vein: Diverse Cases and Surgery Insights

September 9, 2025

Advancing Precision Psychiatry in Eating Disorders

September 9, 2025

Peanut Shell Biochar Composite Demonstrates Potential in Eliminating Antibiotic-Resistant Bacteria from Aquaculture Wastewater

September 9, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Glaucoma Treatment Insights from French Nationwide Survey

Boosting Sorafenib Efficacy via Dipeptidyl Peptidase 9 Inhibition

Preduodenal Portal Vein: Diverse Cases and Surgery Insights

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.